文献速递外周动脉疾病

钙化股腘动脉病变腔内治疗两年结局与风险因素:Evolusion研究

Endovascular Treatment for Calcified Femoropopliteal Peripheral Artery Disease and Risk Factor Identification: Two Year Outcomes of the Evolusion Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-10-04

Evolusion研究前瞻性纳入944例中重度钙化股腘动脉病患者,随访2年,CD-TLR累计9.27%,MALE 11.41%,MACE 8.24%,免于全因死亡82.29%。既往靶肢体干预和严重钙化独立预测MALE,慢性肾病和CLTI与全因死亡升高相关,术后降脂治疗为潜在保护因素。

要点

  • 中重度钙化股腘动脉病变腔内治疗2年CD-TLR为9.27%,MALE为11.41%。
  • 既往靶肢体干预和严重钙化独立预测MALE。
  • 慢性肾病和CLTI与全因死亡升高相关,术后降脂治疗为潜在保护因素。

核心结论

  • 报告了中国人群中重度钙化股腘动脉病变腔内治疗2年结局,并识别潜在独立风险和保护因素以辅助风险分层和治疗决策。

主要发现

  • 1、3、6、12、18、24个月累计CD-TLR率分别为0.54%、1.30%、2.54%、5.03%、7.43%、9.27%。
  • 同期MALE率分别为0.97%、1.84%、3.08%、6.27%、9.39%、11.41%,MACE率分别为0.76%、1.63%、3.23%、4.58%、7.51%、8.24%。
  • 免于全因死亡率分别为98.60%、97.39%、95.06%、90.09%、84.35%、82.29%。
  • 随访期间Rutherford分级和VascuQoL评分均显著改善(p < .001)。
  • 既往靶肢体干预(HR 3.81;p = .022)和严重钙化(HR 1.58;p = .029)独立预测MALE。

关键数值与推荐

  • 慢性肾病(HR 2.73;p < .001)和CLTI(HR 2.72;p < .001)与全因死亡升高相关。
  • 术后降脂治疗(HR 0.58;p = .003)为全因死亡的潜在独立保护因素。

临床怎么用

  • 对既往靶肢体干预或严重钙化患者应加强MALE风险监测。
  • 合并慢性肾病或CLTI患者需关注全因死亡风险。
  • 术后降脂治疗可能有助于降低全因死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated two year clinical outcomes of endovascular treatment for femoropopliteal artery disease with moderate to severe calcification in a Chinese cohort and identified predictors of prognosis. METHODS: This was a prospective, observational, multicentre cohort study of patients with moderate to severe calcified femoropopliteal peripheral artery disease prospectively enrolled in the Evolusion study from December 2020 to October 2023 (ClinicalTrials.gov ID: NCT04716361). Outcomes included clinically driven target limb revascularisation (CD-TLR), major adverse limb events (MALEs), major adverse cardiovascular events (MACEs), all cause mortality (ACM), Rutherford classification, and Vascular Quality of Life (VascuQoL) scores. RESULTS: A total of 944 patients (mean age 74.7 years; 67.7% male) were enrolled, with 51.9% diagnosed with chronic limb threatening ischaemia (CLTI) and a 2 year follow up rate of 80.9%. Cumulative CD-TLR rates at 1, 3, 6, 12, 18, and 24 months were 0.54%, 1.30%, 2.54%, 5.03%, 7.43%, and 9.27%, respectively. MALE rates were 0.97%, 1.84%, 3.08%, 6.27%, 9.39%, and 11.41%, and MACE rates were 0.76%, 1.63%, 3.23%, 4.58%, 7.51%, and 8.24%, respectively. Freedom from ACM was 98.60%, 97.39%, 95.06%, 90.09%, 84.35%, and 82.29%. Statistically significant improvements in Rutherford classification and VascuQoL scores were observed throughout follow up (p < .001). Previous target limb intervention (hazard ratio [HR] 3.81; p = .022) and severe calcification (HR 1.58; p = .029) independently predicted MALEs, whereas chronic kidney disease (HR 2.73; p < .001) and CLTI (HR 2.72; p < .001) were associated with a higher ACM. Post-operative lipid lowering therapy (HR 0.58; p = .003) was a potential independent protective factor against ACM events. CONCLUSION: This study reported two year outcomes of endovascular treatment for moderately to severely calcified femoropopliteal artery disease in a Chinese population and identified potential independent risk and protective factors to aid risk stratification and therapeutic decision making.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang B, Xu Y, Yu X, et al. Endovascular Treatment for Calcified Femoropopliteal Peripheral Artery Disease and Risk Factor Identification: Two Year Outcomes of the Evolusion Study. Eur J Vasc Endovasc Surg. 2025. PMID: 41052588. doi:10.1016/j.ejvs.2025.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。